Onctalk

Abstracts in Lung Cancer Worth Noting for ASCO 2008

admin — Tue, 27 May 2008 02:41:10 +0000

I’ve written a couple of posts on what I’d consider to be the top 10 abstracts in lung cancer at the upcoming ASCO conference that are worth discussing further in lung cancer and that I think are likely to have an impact on lung cancer management over the next few years. The list includes some background and commentary on each of these abstracts and is broken into part 1 and part 2.

Significant Improvement in Progression-Free Survival in Advanced NSCLC with Alimta

Dr. West — Sat, 17 May 2008 23:17:04 +0000

There’s a new post on a likely important trial in advanced NSCLC that I think will change the standard of care and lead to use of “maintenance” or early second line use of chemo immediately after first line chemo. The details of the trial and my commentary are in the post on the GRACE website.

New GRACE Post on Molecular Testing for EGFR: Should It Be Routine Practice?

Dr. West — Fri, 09 May 2008 06:36:37 +0000

There’s a new post at the GRACE website on the topic of whether oncologists should do molecular testing routinely for NSCLC tumors. This is the subject of a debate in which I’ll be participating in an upcoming meeting. You can read more about the topic here.

New Post in GRACE Lung Cancer Section

Dr. West — Wed, 07 May 2008 05:05:30 +0000

Dr. Laskin wrote a new post on the GRACE site, here, describing in some detail the negative ESCAPE trial of sorafenib with chemo for first line treatment of advanced NSCLC.

Although we’re mothballing the OncTalk site and not really adding to it, some people have noted that GRACE doesn’t yet offer a way to get alerts when new posts are written. That feature is in the works. In the meantime, I can write a brief note here that triggers an alert until we have the proper mechanism in place.

Biomarkers Predicting Clinical Benefits for BAC Patients Receiving Tarceva

Dr. West — Thu, 01 May 2008 06:35:48 +0000

The second post of the article on tarceva for advanced BAC, based on a clinical trial from Memorial Sloan Kettering Cancer Center, focuses on biomarkers correlated with better and worse results with tarceva. This post is available here on the GRACE website.